Breast Cancer Core Needle Biopsy Market (By Technology; By End-use: Hospitals & Diagnostic Laboratories, Academic & Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Breast Cancer Core Needle Biopsy Market Size and Trends 

The global breast cancer core needle biopsy market size was estimated at around USD 822.03 million in 2023 and it is projected to hit around USD 1,331.37 million by 2033, growing at a CAGR of 4.94% from 2024 to 2033.

Breast Cancer Core Needle Biopsy Market Size 2024 to 2033

Key Pointers

  • North America dominated the market with the largest market share of 46% in 2023.
  • By Technology, the ultrasound-based breast biopsy segment contributed the largest market share of 42% in 2023.
  • By End-use, the hospitals and diagnostic laboratories segment generated the maximum market share of 60% in 2023.

Breast Cancer Core Needle Biopsy Market Overview

The breast cancer core needle biopsy market is witnessing significant growth driven by the increasing prevalence of breast cancer and the demand for minimally invasive diagnostic procedures. Core needle biopsy (CNB) is a preferred diagnostic tool for detecting breast cancer due to its accuracy, minimal invasiveness, and cost-effectiveness. This procedure involves extracting small samples of breast tissue using a hollow needle, which are then analyzed to diagnose the presence and type of cancer.

What are the Growth Factors of Breast Cancer Core Needle Biopsy Market?

The growth of the breast cancer core needle biopsy market is primarily driven by an increasing incidence of breast cancer globally, which necessitates early and accurate diagnostic tools. Additionally, advancements in biopsy technology, including the development of more precise and minimally invasive core needles, have enhanced the effectiveness and safety of these procedures, making them more widely adopted. The rising awareness about the importance of early cancer detection, supported by governmental and non-governmental screening programs, is also contributing significantly to market expansion. Furthermore, the growing preference for minimally invasive procedures among patients and healthcare providers is accelerating the demand for core needle biopsy as an essential diagnostic method in breast cancer care.

What are the Trends in Breast Cancer Core Needle Biopsy Market?

Integration of Artificial Intelligence (AI): AI is increasingly being integrated into diagnostic processes, including core needle biopsies. AI-powered tools can assist in image analysis, helping radiologists and pathologists detect abnormalities with greater accuracy and efficiency.

Personalized Medicine: The move towards personalized medicine is influencing the Breast Cancer Core Needle Biopsy Market. As treatments become more tailored to individual patient profiles, precise diagnostic tools like core needle biopsies are essential for identifying specific cancer types and guiding treatment decisions.

Rising Demand in Emerging Markets: Emerging economies are experiencing an increase in breast cancer cases and improving healthcare infrastructure. This is leading to higher demand for advanced diagnostic tools, including core needle biopsies, as awareness and access to healthcare services expand.

Focus on Patient Comfort and Experience: There is a growing emphasis on improving patient comfort during core needle biopsies. Innovations such as smaller gauge needles and enhanced anesthetic techniques are being developed to reduce pain and anxiety associated with the procedure, thereby improving the overall patient experience.

What are the Key Challenges Faced by Breast Cancer Core Needle Biopsy Market?

Risk of False-Negative Results: One of the primary challenges in the Breast Cancer Core Needle Biopsy Market is the risk of false-negative results, where a biopsy may miss cancerous tissue. This can lead to delayed diagnosis and treatment, impacting patient outcomes and trust in the procedure.

High Procedure Costs: The cost of core needle biopsy procedures can be a significant barrier, particularly in developing regions. Limited access to advanced healthcare facilities and the high expense associated with the necessary imaging equipment can restrict the adoption of this diagnostic method.

Lack of Skilled Professionals: Performing a core needle biopsy requires a high level of expertise and precision. In many regions, there is a shortage of trained radiologists and pathologists, which can affect the accuracy of the procedure and limit its widespread adoption.

Patient Anxiety and Discomfort: Despite being minimally invasive, core needle biopsies can still cause significant anxiety and discomfort for patients. Concerns about pain and the potential need for multiple procedures can deter some individuals from opting for this diagnostic method.

Technology Insights

In 2023, the ultrasound-based breast biopsy segment dominated the global market with a 42% share and is projected to grow at the fastest CAGR during the forecast period. This segment's leadership is driven by the increasing adoption of ultrasound-based biopsies, recognized for their superior benefits. Additionally, the surge in product launches and approvals is anticipated to further boost the segment's growth.

For example, in April 2021, Mammotome launched the HydroMARK breast biopsy site marker, enhancing long-term ultrasound visibility. Similarly, in August 2023, TransMed7, LLC introduced the SpeedBird, an advanced breast biopsy device that facilitates easier image-guided biopsies. These industry advancements are expected to propel segment growth.

The CT-based segment held the second-largest market share, attributed to technological advancements in CT breast biopsies and the growing accessibility of this technology. Moreover, increasing research and development activities are expected to positively influence segment growth. Innovations like FDG PET/CT and FES PET/CT have also enhanced the treatment and diagnostic landscape for metastatic breast cancer.

End-use Insights

In 2023, the hospitals and diagnostic laboratories segment captured a significant 60% market share. The growing number of patient visits to hospitals, coupled with the increasing adoption of advanced instruments and equipment, is fostering a favorable environment for segment growth. This segment is also anticipated to register the fastest CAGR during the forecast period, driven by the rapid installation of biopsy instruments. For instance, in July 2021, five major U.S. hospitals installed GE Healthcare’s advanced biopsy solution, Serena Bright, a development expected to positively impact segment growth.

The academic and research institutes segment is projected to experience substantial growth over the forecast period. Increased investments in academic centers to support research activities are likely to drive segment expansion. For instance, in October 2023, the Bren Simon Comprehensive Cancer Center and Indiana University Melvin received $2.2 million in funding for metastatic breast cancer research.

Regional Insights

North America accounted for the largest share of the global breast cancer core needle biopsy market in 2023, with approximately 46%. This strong market leadership is attributed to the region's advanced healthcare systems, robust research capabilities, and dedicated efforts to raise awareness about early breast cancer detection and management. Renowned medical institutions and diagnostic centers in the U.S. and Canada consistently emphasize the importance of regular screenings. For example, the Mayo Clinic, recognized as a Specialized Program of Research Excellence (SPORE) for breast cancer research by the National Cancer Institute, highlights the significance of these efforts. Such initiatives contribute to higher adoption rates, positioning North America as a market leader.

Breast Cancer Core Needle Biopsy Market Share, By Region, 2023 (%)

A key factor in North America's dominance in breast cancer core needle biopsies is the integration of artificial intelligence (AI) into diagnostic processes. AI-powered tools are widely used across the region to assist pathologists in accurately interpreting biopsy results, reducing subjectivity and potential errors. This technological innovation enhances diagnostic accuracy and underscores the region's commitment to pioneering healthcare solutions. Meanwhile, Asia Pacific is expected to grow at the fastest rate during the forecast period, driven by the rising prevalence of breast cancer and the increasing demand for novel diagnostic technologies.

Who are the Top Manufactures in Breast Cancer Core Needle Biopsy Market?

  • Intact Medical Corporation
  • Ethicon Surgical Technologies
  • Gallini SRL
  • Leica Biosystems Nussloch GmbH
  • Hologic, Inc.
  • Argon Medical Devices
  • Encapsule Medical Devices LLC
  • Cook Medical Incorporated
  • Becton, Dickinson and Company
  • C.R. Bard, Inc.

Breast Cancer Core Needle Biopsy Market Segmentation:

By Technology 

  • MRI-based Breast Biopsy
  • Ultrasound-based Breast Biopsy
  • Mammography-based (Stereotactic) Breast Biopsy
  • CT-based Breast Biopsy
  • Other Image Based Breast Biopsy

By End-use 

  • Hospitals & Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

The global breast cancer core needle biopsy market size was reached at USD 822.03 million in 2023 and it is projected to hit around USD 1,331.37 million by 2033.

The global breast cancer core needle biopsy market is growing at a compound annual growth rate (CAGR) of 4.94% from 2024 to 2033.

The North America region has accounted for the largest breast cancer core needle biopsy market share in 2023.

The leading companies operating in the breast cancer core needle biopsy market are Intact Medical Corporation, Ethicon Endo Surgery, Galini SRL, Leica Biosystems Nussloch GmbH, Hologic Inc., Argon Medical Devices, Encapsule Medical Devices LLC., Cook Medical Incorporated, Becton & Dickinson Company, C.R. Bard, Inc.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Breast Cancer Core Needle Biopsy Market 

5.1. COVID-19 Landscape: Breast Cancer Core Needle Biopsy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Breast Cancer Core Needle Biopsy Market, By Technology

8.1. Breast Cancer Core Needle Biopsy Market, by Technology, 2024-2033

8.1.1. MRI-Based Breast Biopsy

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Ultrasound-Based Breast Biopsy

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Mammography-Based (Stereotactic) Breast Biopsy

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. CT-Based Breast Biopsy

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Other Image Based Breast Biopsy

8.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Breast Cancer Core Needle Biopsy Market, By End-use

9.1. Breast Cancer Core Needle Biopsy Market, by End-use, 2024-2033

9.1.1. Hospitals & Diagnostic Laboratories

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Pharmaceutical & Biotechnology companies

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Academic & Research Institutes

9.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Breast Cancer Core Needle Biopsy Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Technology (2021-2033)

10.1.2. Market Revenue and Forecast, by End-use (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Technology (2021-2033)

10.1.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Technology (2021-2033)

10.1.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Technology (2021-2033)

10.2.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Technology (2021-2033)

10.2.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Technology (2021-2033)

10.2.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Technology (2021-2033)

10.2.5.2. Market Revenue and Forecast, by End-use (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Technology (2021-2033)

10.2.6.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Technology (2021-2033)

10.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Technology (2021-2033)

10.3.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Technology (2021-2033)

10.3.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Technology (2021-2033)

10.3.5.2. Market Revenue and Forecast, by End-use (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Technology (2021-2033)

10.3.6.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Technology (2021-2033)

10.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Technology (2021-2033)

10.4.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Technology (2021-2033)

10.4.4.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Technology (2021-2033)

10.4.5.2. Market Revenue and Forecast, by End-use (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Technology (2021-2033)

10.4.6.2. Market Revenue and Forecast, by End-use (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Technology (2021-2033)

10.5.2. Market Revenue and Forecast, by End-use (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Technology (2021-2033)

10.5.3.2. Market Revenue and Forecast, by End-use (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Technology (2021-2033)

10.5.4.2. Market Revenue and Forecast, by End-use (2021-2033)

Chapter 11. Company Profiles

11.1. Intact Medical Corporation

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Ethicon Endo Surgery

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Galini SRL

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Leica Biosystems Nussloch GmbH

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. LTE Scientific

11.5. Hologic Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Argon Medical Devices

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Encapsule Medical Devices LLC.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Cook Medical Incorporated

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Becton & Dickinson Company

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. C.R. Bard, Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers